

# pCpGrich-mcs

A CpG-containing control plasmid

Catalog # pcpgr-mcs

## For research use only

Version 21F04-MM

## PRODUCT INFORMATION

### Content:

- 20 µg of pCpGrich-mcs plasmid provided as lyophilized DNA
- *E. coli* GT115 strain provided lyophilized on a paper disk
- 1 ml of Zeocin™ (100 mg/ml)

### Storage and Stability:

- Products are shipped at room temperature.
- Lyophilized DNA is stable 1 year when stored at -20°C.
- Resuspended DNA is stable 6 months when stored at -20°C.
- Bacteria should be stored at -20°C and are stable up to 1 year.
- Store Zeocin™ at 4 °C or at -20 °C. The expiry date is specified on the product label.

### Quality control:

Plasmid construct has been confirmed by restriction analysis and sequencing. Plasmid DNA was purified by ion exchange chromatography and lyophilized. Viability of the lyophilized bacteria upon resuspension has been verified.

## GENERAL PRODUCT USE

InvivoGen has developed a new family of plasmids that are completely devoid of CpG dinucleotides. These plasmids yield high levels of transgene expression both *in vitro* and *in vivo*, and in contrast to CMV-based plasmids allow sustained expression *in vivo*.

pCpGfree plasmids contain elements that naturally lack CpG dinucleotides, were modified to remove all CpGs, or entirely synthesized such as genes encoding selectable markers or reporters. pCpGfree plasmids represent valuable tools to study the effects of CpGs on gene expression *in vivo* and *in vitro*, using cell lines expressing TLR9, as well as their effects on the innate and acquired immune systems.

**pCpGrich-mcs is a CpG-containing control plasmid.** The CpG-free version of the murine CMV enhancer, human EF-1 $\alpha$  promoter, ori R6K gamma, bacterial EM2K promoter and Zeocin™ resistance gene have been replaced by their wild-type (wt) counterparts. The pCpGrich-mcs plasmid contains 88 CpG dinucleotides.

## PLASMID FEATURES

### **Elements for expression in *E. coli***

- R6K gamma ori (wt): This origin of replication is activated by the R6K specific initiator protein  $\pi$ , encoded by the *pir* gene<sup>1</sup>.
- EM7 is a bacterial promoter that enables the constitutive expression of the antibiotic resistance gene in *E. coli*.
- Zeo (wt) selectable marker: *Sh ble* gene confers Zeocin™ resistance.

### **Elements for expression in mammalian cells**

- Mammalian promoter combines the mouse CMV enhancer, the human elongation factor 1 alpha core promoter and 5'UTR containing a synthetic intron (SI 126).
- SV40 pAn: the Simian Virus 40 late polyadenylation signal enables efficient cleavage and polyadenylation reactions resulting in high levels of steady-state mRNA<sup>2</sup>.

• MAR: Matrix attached regions (MARs) are sequences typically AT-rich that are able to form barriers between independently regulated domains<sup>3</sup>. This plasmid contains two MARs, from the 5' region of the human IFN- $\beta$  gene and the  $\beta$ -globin gene. The MARs are placed between the bacterial and mammalian transcription units.

• MCS: The multiple cloning site contains several commonly used restriction sites for convenient cloning of a gene of interest.

5' Bsr GI, Stu I, Bgl II, Acc65 I, Asp 718, Eco O109I, Bsp 120I, Nhe I 3'

**Due to the presence of the R6K origin of replication, pCpG plasmids can only be amplified in *E. coli* mutant strain expressing a *pir* mutant gene. They will not replicate in standard *E. coli* strains. Therefore, pCpG plasmids are provided with the *E. coli* GT115 strain, a *pir* mutant also deficient in *Dcm* methylation.**

1. Wu F. et al. 1995. A DNA segment conferring stable maintenance on R6K gamma-origin core replicons. *J Bacteriol.* 177(22):6338-45. 2. Carswell S. & Alwine JC., 1989. Efficiency of utilization of the simian virus 40 late polyadenylation site: effects of upstream sequences. *Mol. Cell Biol.* 10: 4248-4258. 3. Bode J. et al., 1996. Scaffold/matrix-attached regions: topological switches with multiple regulatory functions. *Crit Rev Eukaryot Gene Expr.* 6(2-3):115-38.

## METHODS

### **Plasmid resuspension**

Quickly spin the tube containing the lyophilized plasmid to pellet the DNA. To obtain a plasmid solution at 1 µg/µl, resuspend the DNA in 20 µl of sterile H<sub>2</sub>O. Store resuspended plasmid at -20 °C.

### **Reconstitution of *E. coli* GT115 strain**

Use sterile conditions to do the following:

1. Reconstitute *E. coli* GT115 by adding 1 ml of Luria-Bertani (LB) medium in the tube containing the paper disk. Let sit for 5 minutes.
2. Mix gently by vortexing for 1-2 minutes.
3. Streak bacteria taken from this suspension on a LB agar plate.
4. Place the plate in an incubator at 37°C overnight.
5. Isolate a single colony and grow the bacteria in LB or terrific broth (TB) medium.
6. Prepare competent cells utilizing protocol of choice.

### **Plasmid amplification and cloning**

Plasmid amplification and cloning can be performed in *E. coli* GT115.

### **Zeocin™ usage**

This antibiotic can be used for *E. coli* at 25 µg/ml in liquid or solid media.

---

### **TECHNICAL SUPPORT**


InvivoGen USA (Toll-Free): 888-457-5873

InvivoGen USA (International): +1 (858) 457-5873

InvivoGen Europe: +33 (0) 5-62-71-69-39

InvivoGen Hong Kong: +852 3-622-34-80

E-mail: info@invivogen.com



*PacI (-1)*

1 TTAATTAAATTATCTAAGGCATGTGAACGGCTGCTTGGTTTCATCTGTACTTCATCTGCTACCTCTGTGACCTG  
 81 AAACATATTATAATTCCATTAAGCTGTGCATATGATAGATTATCATATGTATTTCTTAAAGGATTTGTAAGAAC  
 161 TAATTGAATTGATACCTGAAAGTCTTATCACACTACCCAATAATAATAATCTCTTGTTCAGCTCTGTTCTAT  
 241 AAATATGTACCAGTTTATTGTTTAGTGGTAGTGTATTCTCTTCTATATATACACACATGTGTGCATT  
 321 ATAAATATACAATTATGAATAAAAATTATTAGCAATCAATTGAAAACACTGATTTGTTATGTGAGCAA

---

**SdaI (420)**

EcoRI (415)

401 ACAGCAGATTAAAGGAATTCCCTGCAGGAGATTGTACCTGCCGTACATAAGGTCAATAGGGGGTGAATCAACAGGAAAG  
 481 TCCCATTGGAGCCAAGTACACTGCGTCAATAGGGACTTCCATTGGGTTTGCCTGGTACATAAGGTCAATAGGGATGA  
 561 GTCAATGGGAAAAACCCATTGGAGCCAAGTACACTGACTCAATAGGGACTTCCATTGGGTTTGCCTGGTACATAAGGT  
 641 CAATAGGGGGTGAGTCAACAGGAAAGTCCATTGGAGCCAAGTACATTGAGTCAATAGGGACTTCCAATGGGTTTGC  
 721 CAGTACATAAGGTCAATGGGAGGTAAAGCCAATGGGTTTCCATTACTGGCACGTATACTGAGTCATTAGGGACTTCC  
 801 AATGGGTTTGCCTAGTACATAAGGTCAATAGGGGTGAATCAACAGGAAAGTCCATTGGAGCCAAGTACACTGAGTCA  
 881 TAGGGACTTCCATTGGGTTTGCCTAGTACAAAGGTCAATAGGGGGTGAGTCAATGGGTTTCCATTATTGGCACG

---

**SpeI (981)**

961 TACATAAGGTCAATAGGGGTACTAGTCAGGGCAGAGCGCACATGCCACAGTCCCCGAGAAGTTGGGGGGAGGGGT

---

**AgeI (1050)**

1041 CGGCAATTGAACCGGTGCCTAGAGAAGGTGGCGGGGTAAACTGGAAAGTGTGCTGTACTGGCTCCGCCTTTTC  
 1121 CCGAGGGTGGGGAGAACGTATATAAGTGCAGTAGTTGCCGTGAACGTTCTTTTCGCAACGGGTTGCCAGAAC  
 1201 CAGCTGAAGCTTCTGCCTCTCCCTGTGAGTTGtaagtactgactgtctatgcctggaaagggtggcaggag  
 1281 atggggcagtgcaggaaaagtggcactatgaacctTGAGCCCTAGAcaattgtactaaccttctttccctctcct

---

HindIII (1206)

1361 gacagGTTGGTGTACAGTAGCTTCCAAGGCCTAACAGATCTAGGTACCAAGGGCCATGGCTAGCTGGCCAGACATGATAAG  
 1441 ATACATTGATGAGTTGGACAAACCAACTAGAATGCAGTGAAAAAAATGCTTATTGTGAAATTGTGATGCTATTG  
 1521 CTTTATTGTAACCATTATAAGCTGAATAAACAAAGTTAACACAACAAATTGCATTCTTTATGTTCAGGTTCAGGGG

---

Bsp120I (1408)

Asp718 (1400) NheI (1417)

BglIII (1393) EcoO109I (1407)

BsrGI (1370) StuI (1386) Acc65I (1400) NcoI (1412)

1601 GAGGTGTGGGAGGTTTAAAGCAAGTAAACCTCTACAAATGTGGTATGGAATTCAAGTCAATATGTTACCCCCAAAAA  
 1681 AGCTGTTGTTAACTGCCAACCTCATTCTAAATGTATAGAAGGCCAAAGACAATAACAAAAATATTCTGTAGAA  
 1761 CAAAATGGGAAAGAATGTTCCACTAAATATCAAGATTAGAGCAAAGCATGAGATGTGGGATAGACAGTGAGGCTGA

---

SacI (1852)

1841 TAAAATAGAGTAGAGCTCAGAACAGACCCATTGATATATGTAAGTGACCTATGAAAAAAATATGGCATTTCACAATGGG  
 1921 AAAATGATGGCTTTCTTTAGAAAAACAGGGAAATATATTATGAAAAAATAAAGGAAACCATATGTCA

2001 ACCATACACACAAAAAAATTCCAGTGAATTATAAGTCTAAATGGAGAAGGCAAAACTTAAATCTTTAGAAAATAAT

---

SphI (2084)  
2081 AGAACATGCCATCAA GACTTCAGTGTAGAGAAAATTCTTATGACTCAAAGTCTAACCAAGAAAAGATTGTTAA

---

2161 TTAGATTGCATGAATATTAAGACTTATTTTAAAATTAAGAAAACCATTAAAGAAAAGTCAGGCCATAGAATGACAGAAAAT

---

2241 ATTGCAACACCCCAGTAAAGAGAATTGTAATATGCAGATTATAAAAAGAAGTCTTACAATCAGTAAAAATAAAACTA

---

2321 GACAAAAATTGAACAGATGAAAGAGAACTCTAAATAATCATTACACATGAGAAACTCAATCTCAGAAATCAGAGAACT

---

PacI (2457)  
2401 ATCATTGCATATACTAAATTAGAGAAATTAAAGGCTAAGTAACATCTGTGGCTTAATTAAAATCTCGTAGCACGT  
2481 GTCACTCCTGCTCCTCGGCCACGAAGTGCACGCAGTTGCCGGCGGGTGGCAGGGCGAATCCCGCCCCCACGGCTGC  
125 D Q E E A V F H V C N G A P D R L A F E R G W P Q  
2561 TCGCCGATCTCGGTATGGCCGGCCGGAGGCCTCCCGAAGTCGTGGACACGACCTCCGACCACTCGCGTACAGCTC  
98 E G I E T M A P G S A D R F N T S V V E S W E A Y L E  
2641 GTCCAGGCCGCGACCCACACCCAGGCCAGGGTGTGTCGGCACCCACCTGGCTGGACCGCGCTGATGAACAGGGTC  
72 D L G R V W V W A L T N D P V V Q D Q V A S I F L T V

SmaI (2762)

2721 CGTCGTCCCGGACCACACGGCGAAGTCGTCCCTCACGAAGTCCGGAGAACCCGAGCCGGTGGCCAGAACCTCGACC  
45 D D R V V G A F D D E V F D R S F G L R D T W F E V

NcoI (2852)

2801 GCTCCGGCGACGTGCGCGCGGTGAGCACCGAACGGCACTGGTCAACTTGGCATGGTTAGTTCTCACCTGTCGA  
18 A G A V D R A T L V P V A S T L K A M

AseI (2909) PacI (2927)

2881 TTAACTATGCCATATACTATGCCATGATTAATTGTCAA CACGTGTTAATTAAAGATCAGCAGTTAACCTGTTGATAG

---

SnaBI (2960)  
2961 TACGTACTAAGCTCTCATGTTCACGTACTAACGCTCTCATGTTAACGTACTAACGCTCTCATGTTAACGAACAAACCC

---

3041 TCATGGCTAACGTACTAACGCTCTCATGGCTAACGTACTAACGCTCTCATGTTCACGTACTAACGCTCTCATGTTAACAA

---

AseI (3124)  
3121 TAAAATTAAATAAAATCAGCAACTAAATAGCCTCTAACGGTTAAGTTTATAAGAAAAAAAAGAATATATAAGGCTT

---

HindIII (3202)  
3201 TAAAGCTTTAACGGTTAACGGTTGGACAACAAGCCAGGGATGTAACGCACTGAGAACGCCCTAGAGCCTCTCAAAGC

---

3281 AATTTGAGTGACACAGGAACACTAACGGCTGACAG

---